Deal count and disclosed dollars by women's health sub-sector, compared with the equivalent period before it, and a whitespace read on sub-sectors where research, clinical or product activity is running ahead of capital. Every number is countable against rows in the capital ledger.
| Sub-sector | Rounds | Disclosed | Median | Share of $ | Stage mix | vs prior |
|---|---|---|---|---|---|---|
| Unclassified | 22 | $132M | $3M | 26% | Undisclosed 10 · Pre-seed 4 · Seed 4 · Series A 2 | -49% |
| Devices | 11 | $34M | $800K | 7% | Undisclosed 4 · Seed 3 · Pre-seed 2 · Grant 1 | — |
| Diagnostics | 9 | $161M | $18M | 32% | Seed 4 · Series B 2 · Series A 1 · Pre-seed 1 | — |
| Digital Health/Telehealth | 6 | $45M | $5M | 9% | Grant 3 · Pre-seed 1 · Undisclosed 1 · Series A 1 | — |
| Therapeutics | 4 | $154M | $30M | 30% | Grant 2 · Series E 1 · Series B 1 | — |
The full sub-sector table, change versus the prior period, and the sub-sectors where activity is running ahead of capital.
Sub-sectors with real research, clinical or product activity and almost no recorded capital.
Compiled by OVUM from the capital ledger and the published signal stream. Sub-sector labels are assigned from the wording of each round and signal, so a company can appear in more than one. Amounts are as disclosed.